Advisor Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $2.68M | Buy |
20,294
+1,060
| +6% | +$139K | 0.19% | 107 |
|
|
2022
Q1 | $2.55M | Buy |
19,234
+15
| +0.1% | +$1.8K | 0.16% | 127 |
|
|
2021
Q4 | $2.24M | Sell |
19,219
-1,210
| -6% | -$142K | 0.14% | 150 |
|
|
2021
Q3 | $2.45M | Buy |
20,429
+4,614
| +29% | +$537K | 0.17% | 117 |
|
|
2021
Q2 | $1.9M | Buy |
15,815
+106
| +0.7% | +$11.6K | 0.12% | 165 |
|
|
2021
Q1 | $1.56M | Sell |
15,709
-1,311
| -8% | -$132K | 0.11% | 179 |
|
|
2020
Q4 | $1.7M | Sell |
17,020
-2,704
| -14% | -$286K | 0.13% | 157 |
|
|
2020
Q3 | $2.16M | Buy |
19,724
+1,065
| +6% | +$118K | 0.19% | 103 |
|
|
2020
Q2 | $1.97M | Buy |
18,659
+3,760
| +25% | +$388K | 0.18% | 110 |
|
|
2020
Q1 | $1.33M | Buy |
14,899
+2,459
| +20% | +$231K | 0.16% | 132 |
|
|
2019
Q4 | $1.26M | Buy |
12,440
+436
| +4% | +$41K | 0.13% | 157 |
|
|
2019
Q3 | $1.07M | Buy |
12,004
+1,757
| +17% | +$152K | 0.13% | 170 |
|
|
2019
Q2 | $846K | Buy |
10,247
+236
| +2% | +$18.5K | 0.1% | 200 |
|
|
2019
Q1 | $809K | Sell |
10,011
-40
| -0.4% | -$3.15K | 0.1% | 199 |
|
|
2018
Q4 | $763K | Buy |
10,051
+1,909
| +23% | +$149K | 0.12% | 188 |
|
|
2018
Q3 | $644K | Buy |
8,142
+1,497
| +23% | +$113K | 0.09% | 246 |
|
|
2018
Q2 | $467K | Buy |
6,645
+1,837
| +38% | +$132K | 0.08% | 295 |
|
|
2018
Q1 | $336K | Buy |
4,808
+1,690
| +54% | +$117K | 0.06% | 360 |
|
|
2017
Q4 | $221K | Buy |
+3,118
| New | +$210K | 0.04% | 502 |
|
|
2016
Q1 | – | Sell |
-8,905
| Closed | -$605K | – | 374 |
|
|
2015
Q4 | $605K | Buy |
8,905
+172
| +2% | +$11.3K | 0.21% | 128 |
|
|
2015
Q3 | $556K | Sell |
8,733
-8
| -0.1% | -$526 | 0.23% | 114 |
|
|
2015
Q2 | $559K | Buy |
8,741
+799
| +10% | +$54.7K | 0.21% | 138 |
|
|
2015
Q1 | $543K | Sell |
7,942
-473
| -6% | -$32.9K | 0.23% | 127 |
|
|
2014
Q4 | $611K | Buy |
8,415
+80
| +1% | +$5.73K | 0.27% | 111 |
|
|
2014
Q3 | $595K | Buy |
8,335
+75
| +0.9% | +$5.49K | 0.34% | 93 |
|
|
2014
Q2 | $614K | Sell |
8,260
-24
| -0.3% | -$1.74K | 0.3% | 105 |
|
|
2014
Q1 | $537K | Sell |
8,284
-109
| -1% | -$7.04K | 0.29% | 113 |
|
|
2013
Q4 | $498K | Buy |
8,393
+492
| +6% | +$26.7K | 0.29% | 107 |
|
|
2013
Q3 | $410K | Buy |
7,901
+272
| +4% | +$13.7K | 0.29% | 114 |
|
|
2013
Q2 | $361K | Buy |
+7,629
| New | +$388K | 0.3% | 114 |
|
Other funds holding AZN
Advisor Partners's AZN Position: Q2 2022 in Review
Advisor Partners increased its AstraZeneca (AZN) stake by 5.5% in Q2 2022, buying an estimated $139K and bringing the position to 20,294 shares worth $2.68M. The position accounts for 0.19% of the portfolio, ranked #107.
Advisor Partners first reported a position in AZN in Q2 2013 and has held it in 30 quarters since. 1,016 funds tracked by Wall St. Rank hold AZN as of Q2 2022.
- Advisor Partners held 20,294 shares of AstraZeneca worth $2.68M as of Q2 2022.
- Advisor Partners bought 1,060 AstraZeneca shares in Q2 2022, an estimated $139K.
- AstraZeneca made up 0.19% of Advisor Partners's portfolio in Q2 2022, its #107 holding.
- Advisor Partners first reported a position in AstraZeneca in Q2 2013 and has held it in 30 quarters since.
- 1,016 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.
Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.